Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas

Blood (2018) 132 (Supplement 1): 997.

https://doi.org/10.1182/blood-2018-99-110563

Published: 2018

Journal Articles

Genetically-Defined Diffuse Large B-Cell Lymphoma Subsets Arise By Distinct Pathogenetic Mechanisms and Predict Outcome

Bjoern Chapuy, MD PhD, Chip Stewart, PhD, Andrew Dunford, MS, Jaegil Kim, PhD, Atanas Kamburow, PhD, Robert A. Redd, MS, Michael Lawrence, PhD, Margaretha G.M. Roemer, MSc, Amy Li, Marita Ziepert, PhD, Annette M. Staiger, PhD, Jeremiah Wala, Matthew D. Ducar, MS, Ignaty Leshchiner, PhD, Esther Rheinbay, PhD, Amaro Taylor-Weiner, BS, Caroline Coughlin, BS, Julian Hess, Chandra Pedamallu, Dimitri Livitz, Daniel Rosebrock, Mara Rosenberg, Adam Tracy, Heike Horn, Paul van Hummelen, Andrew L Feldman, MD, Brian K Link, MD, Anne J Novak, PhD, James R. Cerhan, MD PhD, Thomas M Habermann, MD, Reiner Siebert, PhD, Andreas Rosenwald, Aaron R. Thorner, PhD, Matthew Meyerson, MDPhD, Todd R. Golub, MD, Rameen Beroukhim, Gerald Wulf, MD, German Ott, MD, Scott J. Rodig, MDPhD, Stefano Monti, PhD, Donna S. Neuberg, ScD, Markus Loeffler, MD, Michael Pfreundschuh, MD, Lorenz Trümper, MD, Gad Getz, PhD, Margaret A. Shipp, MD

Blood (2017) 130 (Supplement 1): 38.

https://doi.org/10.1182/blood.V130.Suppl_1.38.38

Published: 2017

Journal Articles

Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

Rüdiger Hehlmann, MD, Michael Lauseker, PhD, Susanne Saussele, MD, Markus Pfirrmann, Stefan W. Krause, MD, Hans-Jochem Kolb, MD, Andreas Neubauer, MD, Dieter K. Hossfeld, Christoph Nerl, MD, Alois Gratwohl, MD, Gabriela M. Baerlocher, Dominik Heim, MD, Tim Henrik Bruemmendorf, Alice Fabarius, PhD, Claudia Haferlach, MD, Brigitte Schlegelberger, MD PhD, Martin C. Müller, MD, Sabine Jeromin, PhD, Ulrike Proetel, PhD, Katharina Kohlbrenner, PhD, Astghik Voskanyan, PhD, Sébastien Rinaldetti, Wolfgang Seifarth, PhD, Birgit Spiess, Leopold Balleisen, MD, Maria E Goebeler, MD, Mathias Hänel, MD, Anthony D. Ho, MD, J Dengler, C Falge, Lothar Kanz, MD, Claus-Henning Köhne, MD, PhD, Andreas Burchert, MD, Michael Kneba, MD PhD, Frank Stegelmann, MD, C Köhne, Hans-Walter Lindemann, C Waller, Michael Pfreundschuh, MD, Karsten Spiekermann, Wolfgang E Berdel, MD, L Müller, Matthias Edinger, MD, Jiri Mayer, Prof, MD SCs, Dietrich W Beelen, MD PhD, Martin Bentz, MD, Hartmut Link, MDPhD, Bernd Hertenstein, MD, R Fuchs, Martin Wernli, MD, F Schlegel, Rudolph Schlag, M de Wit, Lorenz Trümper, MD, H Hebarth, M Hahn, Jörg Thomalla, MD, Christof Scheid, MD, Philippe Schafhausen, MD, Walter Verbeek, MD, Michael J. Eckart, MD, Winfried Gassmann, MD PhD, Antonio Pezzutto, MD, Michael Schenk, Peter Brossart, MD, Thomas Geer, MD, Stephan Bildat, E Schäfer, Andreas Hochhaus, MD, Joerg Hasford

Blood (2017) 130 (Supplement 1): 897.

https://doi.org/10.1182/blood.V130.Suppl_1.897.897

Published: 2017

Journal Articles

Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial

Blood (2016) 128 (22): 2978.

https://doi.org/10.1182/blood.V128.22.2978.2978

Published: 2016

Journal Articles

B-cell–specific conditional expression of Myd88 p.L252P leads to the development of diffuse large B-cell lymphoma in mice

Blood (2016) 127 (22): 2732–2741.

https://doi.org/10.1182/blood-2015-11-684183

Published: 2016

Includes: Supplemental data

Journal Articles

Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma

Blood (2015) 126 (23): 3922.

https://doi.org/10.1182/blood.V126.23.3922.3922

Published: 2015

Journal Articles

Populational equilibrium through exosome-mediated Wnt signaling in tumor progression of diffuse large B-cell lymphoma

Raphael Koch, Martin Demant, Thiha Aung, Nina Diering, Anna Cicholas, Bjoern Chapuy, Dirk Wenzel, Marlen Lahmann, Annemarie Güntsch, Christina Kiecke, Sabrina Becker, Timo Hupfeld, Vivek Venkataramani, Marita Ziepert, Lennart Opitz, Wolfram Klapper, Lorenz Trümper, Gerald G. Wulf

Blood (2014) 123 (14): 2189–2198.

https://doi.org/10.1182/blood-2013-08-523886

Published: 2014

Includes: Supplemental data

Journal Articles

A recurrent 11q aberration pattern characterizes a subset of MYC -negative high-grade B-cell lymphomas resembling Burkitt lymphoma

Blood (2014) 123 (8): 1187–1198.

https://doi.org/10.1182/blood-2013-06-507996

Published: 2014

Includes: Supplemental data

Journal Articles

The Prognostic Impact Of Gene Rearrangements and Protein Expression Of MYC, BCL2 and BCL6 In Young High-Risk Patients With DLBCL

Blood (2013) 122 (21): 4262.

https://doi.org/10.1182/blood.V122.21.4262.4262

Published: 2013

Journal Articles

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

Blood (2013) 121 (12): 2253–2263.

https://doi.org/10.1182/blood-2012-06-435842

Published: 2013

Journal Articles

Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results

Myron S. Czuczman, MD, Georg Hess, Ole Gadeberg, Lars Moeller Pedersen, Per Hansen, David Belada, M.D., Ph.D., Stephanie A. Gregory, MD, Brad Pohlman, MD, Jiri Mayer, M.D., PhD., Prof., Robert Pytlik, Lorenz Trumper, Andreas Viardot, MD, Ira V. Gupta, MD, Thomas S. Lin, MD, PhD, Paul Winter, Nancy Goldstein, Roxanne C. Jewell, PhD, Steen Lisby, MD, DMSc

Blood (2012) 120 (21): 1632.

https://doi.org/10.1182/blood.V120.21.1632.1632

Published: 2012

Journal Articles

Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma

Wolfram Klapper, Markus Kreuz, Christian W. Kohler, Birgit Burkhardt, Monika Szczepanowski, Itziar Salaverria, Michael Hummel, Markus Loeffler, Shoji Pellissery, Wilhelm Woessmann, Carsten Schwänen, Lorenz Trümper, Swen Wessendorf, Rainer Spang, Dirk Hasenclever, Reiner Siebert, for the Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe

Blood (2012) 119 (8): 1882–1887.

https://doi.org/10.1182/blood-2011-10-388470

Published: 2012

Includes: Supplemental data

Journal Articles

Paraproteins of familial MGUS/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MM

Sandra Grass, Klaus-Dieter Preuss, Stephan Thome, Dennis D. Weisenburger, Vinetta Witt, Jane Lynch, Florian Zettl, Lorenz Trümper, Natalie Fadle, Evi Regitz, Henry Lynch, Michael Pfreundschuh

Blood (2011) 118 (3): 635–637.

https://doi.org/10.1182/blood-2011-01-331454

Published: 2011

Includes: Supplemental data

Journal Articles

Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults

Blood (2011) 118 (1): 139–147.

https://doi.org/10.1182/blood-2011-01-330795

Published: 2011

Includes: Supplemental data

Journal Articles

Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL

Blood (2010) 116 (23): 4916–4925.

https://doi.org/10.1182/blood-2010-03-276766

Published: 2010

Journal Articles

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

Norbert Schmitz, Lorenz Trümper, Marita Ziepert, Maike Nickelsen, Anthony D. Ho, Bernd Metzner, Norma Peter, Markus Loeffler, Andreas Rosenwald, Michael Pfreundschuh

Blood (2010) 116 (18): 3418–3425.

https://doi.org/10.1182/blood-2010-02-270785

Published: 2010

Includes: Supplemental data

Journal Articles

New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling

Blood (2009) 113 (11): 2488–2497.

https://doi.org/10.1182/blood-2008-04-152900

Published: 2009

Includes: Supplemental data

Journal Articles

Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials

Blood (2008) 112 (4): 1374–1381.

https://doi.org/10.1182/blood-2008-01-136465

Published: 2008

Includes: Supplemental data

Journal Articles

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients

Detlef Haase, Ulrich Germing, Julie Schanz, Michael Pfeilstöcker, Thomas Nösslinger, Barbara Hildebrandt, Andrea Kundgen, Michael Lübbert, Regina Kunzmann, Aristoteles A. N. Giagounidis, Carlo Aul, Lorenz Trümper, Otto Krieger, Reinhard Stauder, Thomas H. Müller, Friedrich Wimazal, Peter Valent, Christa Fonatsch, Christian Steidl

Blood (2007) 110 (13): 4385–4395.

https://doi.org/10.1182/blood-2007-03-082404

Published: 2007

Includes: Supplemental data

Journal Articles

A Randomized Comparison of Total-Marrow Irradiation, Busulfan and Cyclophosphamide with Tandem High-Dose Melphalan in Patients with Multiple Myeloma.

Stefan Knop, MD, Katja Bauer, Holger Hebart, MD, Hannes Wandt, MD, Lorenz Trumper, MD, Peter Liebisch, MD, Georg Maschmeyer, MD, Dietrich Peest, MD, Hans H. Wolf, MD, Nikolaus Kroger, MD, Christian Straka, MD, Michael Pfreundschuh, MD, Paolo Coser, MD, Christoph Meisner, PhD, Lothar Kanz, MD, Hermann Einsele, MD

Blood (2007) 110 (11): 728.

https://doi.org/10.1182/blood.V110.11.728.728

Published: 2007

NARROW

The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas

Genetically-Defined Diffuse Large B-Cell Lymphoma Subsets Arise By Distinct Pathogenetic Mechanisms and Predict Outcome

Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial

B-cell–specific conditional expression of Myd88 p.L252P leads to the development of diffuse large B-cell lymphoma in mice

Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma

Populational equilibrium through exosome-mediated Wnt signaling in tumor progression of diffuse large B-cell lymphoma

A recurrent 11q aberration pattern characterizes a subset of MYC -negative high-grade B-cell lymphomas resembling Burkitt lymphoma

The Prognostic Impact Of Gene Rearrangements and Protein Expression Of MYC, BCL2 and BCL6 In Young High-Risk Patients With DLBCL

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results

Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma

Paraproteins of familial MGUS/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MM

Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults

Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling

Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients

A Randomized Comparison of Total-Marrow Irradiation, Busulfan and Cyclophosphamide with Tandem High-Dose Melphalan in Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only